Statements
Response to Mr Michael Clarke’s personal views ‘NHS sight tests include unevaluated screening examinations’
College Statement The Royal College of Ophthalmologists Issues a Response to Mr Michael Clarke’s personal views expressed in his paper titled ‘NHS sight tests include unevaluated screening examinations that lead to waste’. In a personal view recently published on bmj.com, a leading eye doctor says that opticians are making too many referrals to doctors. Mr
Intravitreal ranibizumab injection for the treatment of choroidal neovascularisation secondary to pathological myopia
College Statement The Royal College of Ophthalmologists welcomes the decision by The National Institute for Health and Care Excellence (NICE) to recommend Ranibizumab 0.5 mg intravitreal injection as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia. Prior to this decision there has been limited / variable access to anti-VEGF
Positive draft final guidance from NICE for Eylea® for the treatment on wet AMD
College Statement The Royal College of Ophthalmologists welcomes the NICE draft final guidance which announces that Eylea® (aflibercept) should be recommended for the treatment of patients with wet age-related macular degeneration (wAMD). Eylea® is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and placental growth factor
Intravitreal Ranibizumab injection for treatment of MO secondary to RVO
College Statement The Royal College of Ophthalmologists welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend 0.5mg ranibizumab intravitreal injection as an option for the treatment of macular oedema secondary to central retinal vein occlusion (CRVO) and selected cases of branch retinal vein occlusion (BRVO) when laser has either
Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly
College Statement This statement refers only to injections of anti –Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly directly through the conjunctiva and sclera using a sharp needle. This statement is the current College position and supersedes older statements on intraocular injections in the ARMD Guidelines for Management (2009) and Maximising Capacity in AMD Services